Cantourage Group SE
Cantourage Group SE
NuWays RecommendationRecommendation
Buy
Price Target
€10.00
Upside
101.61%
Chart
- 1M
- 3M
- 6M
- YTD
- 1Y
- 3Y
€4.96
€0.06 (1.22%)
Realtime-Data from 04.10.2024 15:43:15
Cantourage Group SE, founded in Berlin in 2019, is reshaping the medical cannabis market. By uniting global cultivators' expertise with their own industry experience, they simplify import processes for licensed growers. Cantourage handles regulatory complexities, processing raw materials into EU-compliant end products sold through wholesalers and pharmacies. With a network spanning 50 suppliers from 15 countries, they offer a diverse range of high-quality products. In September 2023, Cantourage also launched its own telemedicine platform for medical cannabis, telecan°, to better benefit from Germany’s de-classification of cannabis as a narcotic drug in April 2024.
Ticker
HIGH GR
Market Cap
€61.84 M
Enterprise Value
€64.44 M
26 week avg vol.
5080
Primar Exchange
Scale
IPO
2022
Sector
Health Care & Pharma
Headquarters
Berlin, DE
Employees
50
Incorporated
2019
CEO
Philip Schetter
Website
Florian Holzapfel
22.70%
Patrick Hoffmann
22.70%
PiFriva Verwaltungs - und Beteiligungs GmbH
17.90%
Think.Health
12.70%
Constanze Pelze
4.60%
Free Float
19.40%
31.10.2024
Publication half yearly financial report
KPIs in EUR
KPI | 2023 | 2024e | 2025e |
---|---|---|---|
Sales | 23.56 M | 42.78 M | 54.00 M |
EBITDA | (254.44 K) | 1.79 M | 4.52 M |
EBIT | (4.33 M) | (2.44 M) | 110.18 K |
EPS | (0.34) | (0.14) | 0.01 |
FCF | (3.14 M) | 439.85 K | 1.22 M |
Valuation
KPI | 2023 | 2024e | 2025e |
---|---|---|---|
EV / Sales | 2.74x | 1.41x | 1.10x |
EV / EBITDA | (253.26x) | 33.68x | 13.10x |
EV / EBIT | (14.89x) | (24.70x) | 536.91x |
Price / Earnings | (14.71x) | (36.13x) | 801.78x |
EV / FCF | (20.50x) | 137.27x | 48.53x |
Downloads
Latest Research
Initiation